In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Nektar Therapeutics’s stock clocked out at $0.55, down -8.09% from its previous closing price of $0.60. In other words, the price has decreased by -$8.09 from its previous closing price. On the day, 4.72 million shares were traded. NKTR stock price reached its highest trading level at $0.6 during the session, while it also had its lowest trading level at $0.5313.
Ratios:
To gain a deeper understanding of NKTR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.26 and its Current Ratio is at 4.26. In the meantime, Its Debt-to-Equity ratio is 3.20 whereas as Long-Term Debt/Eq ratio is at 2.87.
On January 08, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.
On December 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.50.H.C. Wainwright initiated its Buy rating on December 10, 2024, with a $6.50 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 19 ’25 when Zalevsky Jonathan sold 10,300 shares for $1.01 per share. The transaction valued at 10,403 led to the insider holds 316,604 shares of the business.
Wilson Mark Andrew sold 11,040 shares of NKTR for $11,150 on Feb 19 ’25. The Chief Legal Officer now owns 324,292 shares after completing the transaction at $1.01 per share. On Feb 19 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 23,774 shares for $1.01 each. As a result, the insider received 24,012 and left with 1,086,901 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 102710800 and an Enterprise Value of 41824572. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.04 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 0.425 whereas that against EBITDA is -0.333.
Stock Price History:
The Beta on a monthly basis for NKTR is 0.68, which has changed by -0.58015263 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.58. The 50-Day Moving Average of the stock is -32.45%, while the 200-Day Moving Average is calculated to be -49.91%.
Shares Statistics:
It appears that NKTR traded 2.13M shares on average per day over the past three months and 2531700 shares per day over the past ten days. A total of 185.78M shares are outstanding, with a floating share count of 179.37M. Insiders hold about 3.62% of the company’s shares, while institutions hold 69.47% stake in the company. Shares short for NKTR as of 1741910400 were 6947547 with a Short Ratio of 3.26, compared to 1739491200 on 7477125. Therefore, it implies a Short% of Shares Outstanding of 6947547 and a Short% of Float of 4.760000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
